Exelixis, Inc. (EXEL)
USD 35.2
(2.15%)
USD 35.2
(2.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 207.76 Million USD | 13.98% |
| 2022 | 182.28 Million USD | -21.11% |
| 2021 | 231.06 Million USD | 106.71% |
| 2020 | 111.78 Million USD | -65.18% |
| 2019 | 321.01 Million USD | -53.48% |
| 2018 | 690.07 Million USD | 347.44% |
| 2017 | 154.22 Million USD | 319.63% |
| 2016 | -70.22 Million USD | 58.63% |
| 2015 | -169.73 Million USD | 36.79% |
| 2014 | -268.54 Million USD | -9.72% |
| 2013 | -244.76 Million USD | -65.78% |
| 2012 | -147.64 Million USD | -295.05% |
| 2011 | 75.69 Million USD | 181.99% |
| 2010 | -92.33 Million USD | 31.72% |
| 2009 | -135.22 Million USD | 16.97% |
| 2008 | -162.85 Million USD | -88.53% |
| 2007 | -86.38 Million USD | 14.89% |
| 2006 | -101.49 Million USD | -20.25% |
| 2005 | -84.4 Million USD | 38.5% |
| 2004 | -137.24 Million USD | -44.81% |
| 2003 | -94.77 Million USD | -10.04% |
| 2002 | -86.13 Million USD | -20.99% |
| 2001 | -71.18 Million USD | 5.48% |
| 2000 | -75.31 Million USD | -302.73% |
| 1999 | -18.7 Million USD | -19.37% |
| 1998 | -15.66 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 117.97 Million USD | -47.83% |
| 2024 Q1 | 37.31 Million USD | -56.36% |
| 2024 Q2 | 226.11 Million USD | 505.93% |
| 2023 Q3 | 1.04 Million USD | -98.72% |
| 2023 Q4 | 85.51 Million USD | 8114.99% |
| 2023 Q1 | 40.02 Million USD | 232.66% |
| 2023 Q2 | 81.17 Million USD | 102.8% |
| 2023 FY | 207.76 Million USD | 13.98% |
| 2022 Q1 | 68.57 Million USD | -27.94% |
| 2022 Q4 | -30.17 Million USD | -141.21% |
| 2022 Q3 | 73.21 Million USD | 3.59% |
| 2022 FY | 182.28 Million USD | -21.11% |
| 2022 Q2 | 70.67 Million USD | 3.06% |
| 2021 Q4 | 95.16 Million USD | 149.1% |
| 2021 FY | 231.06 Million USD | 106.71% |
| 2021 Q1 | 1.6 Million USD | -94.36% |
| 2021 Q2 | 96.09 Million USD | 5902.0% |
| 2021 Q3 | 38.2 Million USD | -60.24% |
| 2020 Q2 | 66.82 Million USD | 37.46% |
| 2020 FY | 111.78 Million USD | -65.18% |
| 2020 Q3 | -32.04 Million USD | -147.95% |
| 2020 Q4 | 28.38 Million USD | 188.6% |
| 2020 Q1 | 48.61 Million USD | -29.28% |
| 2019 FY | 321.01 Million USD | -53.48% |
| 2019 Q2 | 79.04 Million USD | 4.31% |
| 2019 Q1 | 75.77 Million USD | -78.96% |
| 2019 Q4 | 68.74 Million USD | -29.46% |
| 2019 Q3 | 97.45 Million USD | 23.29% |
| 2018 Q2 | 87.49 Million USD | -24.48% |
| 2018 FY | 690.07 Million USD | 347.44% |
| 2018 Q1 | 115.85 Million USD | 201.01% |
| 2018 Q3 | 126.63 Million USD | 44.73% |
| 2018 Q4 | 360.08 Million USD | 184.36% |
| 2017 Q2 | 17.65 Million USD | 5.72% |
| 2017 Q3 | 81.38 Million USD | 360.93% |
| 2017 FY | 154.22 Million USD | 319.63% |
| 2017 Q1 | 16.7 Million USD | -52.45% |
| 2017 Q4 | 38.48 Million USD | -52.71% |
| 2016 Q2 | -37.01 Million USD | 39.66% |
| 2016 FY | -70.22 Million USD | 58.63% |
| 2016 Q3 | -11.28 Million USD | 69.52% |
| 2016 Q4 | 35.12 Million USD | 411.26% |
| 2016 Q1 | -61.34 Million USD | -40.57% |
| 2015 FY | -169.73 Million USD | 36.79% |
| 2015 Q4 | -43.64 Million USD | 8.25% |
| 2015 Q3 | -47.56 Million USD | -9.69% |
| 2015 Q2 | -43.36 Million USD | -23.29% |
| 2015 Q1 | -35.17 Million USD | 39.31% |
| 2014 Q2 | -73.41 Million USD | 1.62% |
| 2014 Q3 | -62.56 Million USD | 14.78% |
| 2014 Q1 | -74.61 Million USD | -5.47% |
| 2014 Q4 | -57.95 Million USD | 7.36% |
| 2014 FY | -268.54 Million USD | -9.72% |
| 2013 Q1 | -44.72 Million USD | 14.3% |
| 2013 FY | -244.76 Million USD | -65.78% |
| 2013 Q2 | -62.16 Million USD | -38.97% |
| 2013 Q4 | -70.74 Million USD | -5.4% |
| 2013 Q3 | -67.12 Million USD | -7.98% |
| 2012 Q3 | -32.81 Million USD | 10.07% |
| 2012 Q4 | -52.19 Million USD | -59.06% |
| 2012 Q2 | -36.48 Million USD | -39.52% |
| 2012 Q1 | -26.15 Million USD | -156.49% |
| 2012 FY | -147.64 Million USD | -295.05% |
| 2011 FY | 75.69 Million USD | 181.99% |
| 2011 Q1 | -27.49 Million USD | -53.88% |
| 2011 Q2 | -20.97 Million USD | 23.7% |
| 2011 Q3 | 77.86 Million USD | 471.23% |
| 2011 Q4 | 46.29 Million USD | -40.54% |
| 2010 Q2 | -22.61 Million USD | 47.71% |
| 2010 Q4 | -17.86 Million USD | -107.66% |
| 2010 FY | -92.33 Million USD | 31.72% |
| 2010 Q1 | -43.24 Million USD | -49.99% |
| 2010 Q3 | -8.6 Million USD | 61.96% |
| 2009 Q1 | -36.18 Million USD | 4.66% |
| 2009 Q4 | -28.83 Million USD | -13.32% |
| 2009 Q3 | -25.44 Million USD | 43.15% |
| 2009 Q2 | -44.76 Million USD | -23.72% |
| 2009 FY | -135.22 Million USD | 16.97% |
| 2008 Q3 | -38.5 Million USD | 14.67% |
| 2008 Q2 | -45.12 Million USD | -9.33% |
| 2008 FY | -162.85 Million USD | -88.53% |
| 2008 Q1 | -41.27 Million USD | -107.18% |
| 2008 Q4 | -37.94 Million USD | 1.45% |
| 2007 Q1 | -24.2 Million USD | 3.9% |
| 2007 Q2 | -28.56 Million USD | -18.02% |
| 2007 Q3 | -13.69 Million USD | 52.05% |
| 2007 FY | -86.38 Million USD | 14.89% |
| 2007 Q4 | -19.92 Million USD | -45.46% |
| 2006 FY | -101.49 Million USD | -20.25% |
| 2006 Q1 | -27.12 Million USD | -10.61% |
| 2006 Q2 | -23.99 Million USD | 11.55% |
| 2006 Q3 | -25.19 Million USD | -5.03% |
| 2006 Q4 | -25.18 Million USD | 0.06% |
| 2005 Q3 | -22.77 Million USD | -134.89% |
| 2005 FY | -84.4 Million USD | 38.5% |
| 2005 Q2 | -9.69 Million USD | 64.63% |
| 2005 Q1 | -27.41 Million USD | 47.21% |
| 2005 Q4 | -24.52 Million USD | -7.67% |
| 2004 Q4 | -51.92 Million USD | -90.97% |
| 2004 FY | -137.24 Million USD | -44.81% |
| 2004 Q1 | -28.84 Million USD | -23.9% |
| 2004 Q3 | -27.18 Million USD | 7.18% |
| 2004 Q2 | -29.29 Million USD | -1.55% |
| 2003 Q1 | -23.05 Million USD | -10.52% |
| 2003 Q2 | -23.44 Million USD | -1.67% |
| 2003 Q3 | -24.99 Million USD | -6.62% |
| 2003 FY | -94.77 Million USD | -10.04% |
| 2003 Q4 | -23.27 Million USD | 6.87% |
| 2002 Q3 | -22.94 Million USD | 4.02% |
| 2002 Q1 | -18.42 Million USD | -0.83% |
| 2002 Q2 | -23.9 Million USD | -29.76% |
| 2002 FY | -86.13 Million USD | -20.99% |
| 2002 Q4 | -20.86 Million USD | 9.07% |
| 2001 Q2 | -23.7 Million USD | -86.4% |
| 2001 Q3 | -16.49 Million USD | 30.45% |
| 2001 Q4 | -18.26 Million USD | -10.79% |
| 2001 FY | -71.18 Million USD | 5.48% |
| 2001 Q1 | -12.71 Million USD | 73.53% |
| 2000 FY | -75.31 Million USD | -302.73% |
| 2000 Q2 | -10.97 Million USD | -50.57% |
| 2000 Q3 | -8.99 Million USD | 17.98% |
| 2000 Q1 | -7.28 Million USD | 0.0% |
| 2000 Q4 | -48.05 Million USD | -433.97% |
| 1999 FY | -18.7 Million USD | -19.37% |
| 1998 FY | -15.66 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -102.07 Million USD | 303.551% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 1191.84% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 691.249% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 506.92% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 203.062% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 256.812% |
| Agenus Inc. | -245.76 Million USD | 184.539% |
| Fortress Biotech, Inc. | -60.63 Million USD | 442.637% |
| GlycoMimetics, Inc. | -36.89 Million USD | 663.058% |
| Novavax, Inc. | -545.06 Million USD | 138.118% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 235.801% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 22297.115% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 311.688% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 3207.928% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 500.125% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 147.193% |
| AlloVir, Inc. | -190.41 Million USD | 209.11% |
| Aptorum Group Limited | -2.82 Million USD | 7455.432% |
| Ardelyx, Inc. | -66.06 Million USD | 414.476% |
| Bicycle Therapeutics plc | -180.66 Million USD | 215.001% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 216.035% |
| Chimerix, Inc. | -82.09 Million USD | 353.079% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 565.806% |
| CRISPR Therapeutics AG | -153.61 Million USD | 235.255% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 739.572% |
| Precision BioSciences, Inc. | -61.31 Million USD | 438.826% |
| Dyadic International, Inc. | -6.79 Million USD | 3157.408% |
| Elevation Oncology, Inc. | -45.7 Million USD | 554.588% |
| Fortress Biotech, Inc. | -60.63 Million USD | 442.637% |
| GT Biopharma, Inc. | -7.59 Million USD | 2834.83% |
| Alkermes plc | 355.75 Million USD | 41.599% |
| Immix Biopharma, Inc. | -15.42 Million USD | 1446.845% |
| Innoviva, Inc. | 179.72 Million USD | -15.604% |
| IO Biotech, Inc. | -86.08 Million USD | 341.354% |
| Jaguar Health, Inc. | -41.3 Million USD | 603.063% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -298.368% |
| ContextLogic Inc. | -317 Million USD | 165.541% |
| AbCellera Biologics Inc. | -146.39 Million USD | 241.918% |
| Lantern Pharma Inc. | -15.96 Million USD | 1401.661% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2544.007% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 201.213% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 155.607% |
| MEI Pharma, Inc. | 17.77 Million USD | -1068.664% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 383.263% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 953.62% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 246.929% |
| NextCure, Inc. | -62.72 Million USD | 431.242% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 354.676% |
| ChromaDex Corporation | -4.93 Million USD | 4307.473% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 283.926% |
| Incyte Corporation | 597.59 Million USD | 65.233% |
| Opthea Limited | -220.24 Million USD | 194.335% |
| MiMedx Group, Inc. | 67.43 Million USD | -208.078% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 452.248% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 415.92% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 506.116% |
| Vaxcyte, Inc. | -402.26 Million USD | 151.649% |
| PDS Biotechnology Corporation | -42.94 Million USD | 583.825% |
| Pharming Group N.V. | -10.54 Million USD | 2069.71% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 946.535% |
| Onconetix, Inc. | -37.4 Million USD | 655.377% |
| Acelyrin, Inc. | -381.64 Million USD | 154.44% |
| PureTech Health plc | -65.69 Million USD | 416.247% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 381.563% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 197.901% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 1220.263% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 953.62% |
| ESSA Pharma Inc. | -26.58 Million USD | 881.59% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 928.046% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 2180.563% |
| Seer, Inc. | -86.27 Million USD | 340.812% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 180.582% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 656.414% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 862.776% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 1656562.848% |
| Summit Therapeutics Inc. | -614.92 Million USD | 133.787% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 709.264% |
| Senti Biosciences, Inc. | -92.91 Million USD | 323.598% |
| ImmuCell Corporation | -5.77 Million USD | 3697.913% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 226.244% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 456.415% |
| Precigen, Inc. | -95.9 Million USD | 316.639% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 481.767% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 626.267% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 298.44% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 433.732% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 1689.406% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 136.269% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 410.12% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 807.598% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 830.23% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1123.927% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 461.249% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 229.104% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 5890.552% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 186.081% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -190.947% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 522.974% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 2188.564% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 184.597% |
| Aptose Biosciences Inc. | -51.2 Million USD | 505.736% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 311.363% |
| Soligenix, Inc. | -6.14 Million USD | 3483.393% |
| Century Therapeutics, Inc. | -136.67 Million USD | 252.016% |
| Kura Oncology, Inc. | -152.63 Million USD | 236.122% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 332.873% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 2071.579% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -36642.002% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 36614.06% |
| Autolus Therapeutics plc | -208.38 Million USD | 199.703% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 388.972% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 393.474% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 1058.856% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 192.238% |
| GRI Bio, Inc. | -13.03 Million USD | 1693.657% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 5125.059% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 267.439% |
| IGM Biosciences, Inc. | -246.41 Million USD | 184.315% |
| INmune Bio, Inc. | -30 Million USD | 792.365% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 287.922% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 592.407% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1401.65% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 1415.386% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 448.103% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 305.368% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 175.243% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 187.336% |
| Verastem, Inc. | -87.36 Million USD | 337.807% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 483.415% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 228.778% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 278.098% |
| Histogen Inc. | -10.62 Million USD | 2056.172% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 1554.249% |
| Surrozen, Inc. | -43.04 Million USD | 582.703% |
| Organovo Holdings, Inc. | -14.67 Million USD | 1516.161% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 4184.211% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 496.961% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 922.408% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 871.271% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 2586.094% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 237.515% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 524.651% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 798.957% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 2094.345% |
| Apollomics, Inc. | -172.6 Million USD | 220.373% |
| Amarin Corporation plc | -59.11 Million USD | 451.477% |
| Mesoblast Limited | -87.95 Million USD | 336.215% |
| Turnstone Biologics Corp. | -55.2 Million USD | 476.386% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 241.373% |
| Synaptogenix, Inc. | -6.03 Million USD | 3540.67% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 1381.867% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 366.297% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 4436.147% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 2572.746% |
| Better Therapeutics, Inc. | -39.76 Million USD | 622.548% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 244.333% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 139.303% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1806.905% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 2765.468% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 775.681% |
| Gritstone bio, Inc. | -138.49 Million USD | 250.022% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 422.291% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 5294.19% |
| Avid Bioservices, Inc. | -140.75 Million USD | 247.61% |
| Insmed Incorporated | -749.56 Million USD | 127.718% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 1467.819% |
| MediWound Ltd. | -6.71 Million USD | 3193.582% |
| OmniAb, Inc. | -50.61 Million USD | 510.449% |
| Alector, Inc. | -130.39 Million USD | 259.34% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 282.692% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 500.727% |
| Zai Lab Limited | -334.62 Million USD | 162.09% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 164.128% |
| Aura Biosciences, Inc. | -76.4 Million USD | 371.915% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 188.549% |
| Immunic, Inc. | -93.61 Million USD | 321.943% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 252.889% |
| Veracyte, Inc. | -74.4 Million USD | 379.239% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 2806.842% |
| FibroGen, Inc. | -284.23 Million USD | 173.097% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 892.029% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 3067.27% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 1203.214% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 49.916% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 1021.148% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -321.678% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1539.56% |
| Galecto, Inc. | -38.34 Million USD | 641.774% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 1201.267% |
| Fortrea Holdings Inc. | -3.4 Million USD | 6210.735% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 264.054% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 1293.297% |
| XBiotech Inc. | -24.55 Million USD | 946.052% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 422.291% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 431.469% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 311.088% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 1069.641% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 476.434% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 134.249% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 404.395% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 365022.542% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 191.713% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 1033.041% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 194.563% |
| NexImmune, Inc. | -32.34 Million USD | 742.352% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 4030.05% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 1579.187% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 94.745% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 957.789% |
| Scopus BioPharma Inc. | -11.6 Million USD | 1889.562% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 277.884% |
| Ainos, Inc. | -13.77 Million USD | 1608.763% |
| Pluri Inc. | -20.88 Million USD | 1094.662% |
| Prothena Corporation plc | -147.02 Million USD | 241.31% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 282.456% |
| Celularity Inc. | -196.29 Million USD | 205.843% |
| Rallybio Corporation | -74.56 Million USD | 378.64% |
| Cue Biopharma, Inc. | -50.73 Million USD | 509.526% |
| MeiraGTx Holdings plc | -84.02 Million USD | 347.26% |
| Omeros Corporation | -117.81 Million USD | 276.352% |
| Humacyte, Inc. | -110.77 Million USD | 287.554% |
| Immunocore Holdings plc | -55.28 Million USD | 475.794% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 1255.277% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 1006.044% |
| Blueprint Medicines Corporation | -506.98 Million USD | 140.981% |
| CalciMedica, Inc. | -34.35 Million USD | 704.724% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 407.004% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 225.319% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 173.349% |
| Pulmatrix, Inc. | -14.12 Million USD | 1571.319% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 690.325% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 351.416% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 143.177% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 298.115% |
| Cytokinetics, Incorporated | -526.24 Million USD | 139.481% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 676.085% |
| Nutriband Inc. | -5.48 Million USD | 3887.659% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 614.015% |
| Vor Biopharma Inc. | -117.86 Million USD | 276.277% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 95.223% |
| Evogene Ltd. | -23.87 Million USD | 970.074% |
| ProKidney Corp. | -35.46 Million USD | 685.782% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 273.48% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 2748.243% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 132.302% |
| CorMedix Inc. | -46.33 Million USD | 548.357% |
| BioLineRx Ltd. | -60.61 Million USD | 442.767% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 304.204% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 605.929% |
| Atai Life Sciences N.V. | -40.22 Million USD | 616.52% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 357.613% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 375.109% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 171.106% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 845.319% |
| MediciNova, Inc. | -8.57 Million USD | 2523.9% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 268.535% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2580.233% |
| GeoVax Labs, Inc. | -25.96 Million USD | 900.119% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 186.844% |
| Biomea Fusion, Inc. | -117.25 Million USD | 277.191% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 133.157% |
| Mereo BioPharma Group plc | -29.46 Million USD | 805.101% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 235.65% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 199.238% |
| Absci Corporation | -110.56 Million USD | 287.91% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 789.104% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 306.04% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 188.06% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -1375.185% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 207.671% |
| Allakos Inc. | -185.7 Million USD | 211.881% |
| Imunon, Inc. | -19.51 Million USD | 1164.644% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 313.454% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -95.746% |
| BioAtla, Inc. | -123.46 Million USD | 268.283% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1806.905% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 1392.232% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 163.485% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 662.302% |
| XOMA Corporation | -40.83 Million USD | 608.841% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 303.951% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 275.31% |
| aTyr Pharma, Inc. | -50.38 Million USD | 512.322% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 336.961% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 236.905% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 187.394% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 691.603% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 2667.555% |
| Akari Therapeutics, Plc | -10 Million USD | 2175.989% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 308700.074% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 26.218% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 3217.302% |
| UroGen Pharma Ltd. | -102.24 Million USD | 303.205% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 294.549% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 2771.468% |
| Orgenesis Inc. | -55.36 Million USD | 475.291% |
| Entera Bio Ltd. | -8.88 Million USD | 2437.327% |
| GH Research PLC | -35.58 Million USD | 683.823% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 1096.953% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 368.472% |
| Xencor, Inc. | -126.08 Million USD | 264.779% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 5617.298% |
| Replimune Group, Inc. | -215.79 Million USD | 196.279% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 1076.957% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -8180.789% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 3217.302% |
| Portage Biotech Inc. | -75.33 Million USD | 375.774% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2580.233% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 314.955% |
| OncoCyte Corporation | -27.78 Million USD | 847.867% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 1648.496% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 1968.135% |
| Purple Biotech Ltd. | -19.88 Million USD | 1145.096% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 3060.037% |
| scPharmaceuticals Inc. | -54.81 Million USD | 479.064% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 1286.812% |
| HilleVax, Inc. | -123.56 Million USD | 268.141% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 2155.654% |
| Tharimmune, Inc. | -9.31 Million USD | 2329.455% |
| Genprex, Inc. | -30.86 Million USD | 773.24% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 188.064% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 790.387% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 11759.091% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 4023.044% |
| OKYO Pharma Limited | -16.82 Thousand USD | 1234925.081% |
| Savara Inc. | -54.69 Million USD | 479.84% |
| Curis, Inc. | -47.41 Million USD | 538.203% |
| Daré Bioscience, Inc. | -30.16 Million USD | 788.844% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 1445.185% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 3830.742% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 796.847% |
| BeiGene, Ltd. | -881.7 Million USD | 123.564% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 1075.697% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 147.612% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 363.144% |
| Erasca, Inc. | -125.04 Million USD | 266.156% |
| bluebird bio, Inc. | -211.91 Million USD | 198.043% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 4254.887% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -23.932% |
| DBV Technologies S.A. | -72.72 Million USD | 385.682% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 4254.887% |
| Moderna, Inc. | -4.71 Billion USD | 104.407% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 617.382% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 3748.841% |
| Molecular Templates, Inc. | -8.12 Million USD | 2657.422% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 444.05% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 286.505% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 253.5% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 533.575% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 246.904% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 207.98% |
| MacroGenics, Inc. | -9.05 Million USD | 2393.718% |
| RenovoRx, Inc. | -10.23 Million USD | 2130.541% |
| Adicet Bio, Inc. | -142.65 Million USD | 245.639% |
| Prime Medicine, Inc. | -198.13 Million USD | 204.861% |
| Aditxt, Inc. | -32.38 Million USD | 741.629% |
| Adagene Inc. | -18.94 Million USD | 1196.595% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2941.533% |
| Quantum-Si incorporated | -95.96 Million USD | 316.512% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 274.55% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1525.218% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -57.005% |
| SciSparc Ltd. | -5.12 Million USD | 4156.326% |
| Vericel Corporation | -3.18 Million USD | 6629.384% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 172871.8% |
| Minerva Neurosciences, Inc. | -30 Million USD | 792.426% |
| Generation Bio Co. | -126.61 Million USD | 264.096% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 385.035% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 352.014% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 179.257% |
| Invivyd, Inc. | -198.64 Million USD | 204.592% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 160.755% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 2491.795% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -811.01% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 2204.162% |
| 2seventy bio, Inc. | -217.57 Million USD | 195.493% |
| ADMA Biologics, Inc. | -28.23 Million USD | 835.738% |
| Clene Inc. | -49.5 Million USD | 519.693% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 1032.202% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 520.288% |
| GeoVax Labs, Inc. | -25.96 Million USD | 900.119% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 163.33% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 738.434% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -814.459% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 310.306% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 377.932% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 229.203% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 133.78% |
| Evaxion Biotech A/S | -22.12 Million USD | 1039.051% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 357.339% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 203.847% |
| Trevena, Inc. | -40.28 Million USD | 615.687% |
| Surrozen, Inc. | -43.04 Million USD | 582.703% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 400.525% |
| Cingulate Inc. | -23.53 Million USD | 982.794% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 3105.859% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 621.237% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 2794.512% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 330.313% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 439.009% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 449.167% |
| Clearmind Medicine Inc. | -11.95 Million USD | 1837.888% |
| Kronos Bio, Inc. | -112.67 Million USD | 284.396% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 400.251% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 8191983.228% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 341.883% |
| Statera Biopharma, Inc. | -174.4 Million USD | 219.126% |
| ImmunityBio, Inc. | -583.19 Million USD | 135.625% |
| Korro Bio, Inc. | -81.17 Million USD | 355.956% |
| Kineta, Inc. | -14.09 Million USD | 1573.615% |
| BioVie Inc. | -32.12 Million USD | 746.829% |
| Codexis, Inc. | -76.24 Million USD | 372.514% |
| Celularity Inc. | -196.29 Million USD | 205.843% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 196.847% |
| Celcuity Inc. | -63.77 Million USD | 425.757% |
| Virax Biolabs Group Limited | -6.73 Million USD | 3185.525% |
| Cibus, Inc. | -267.62 Million USD | 177.632% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 615.214% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 680.171% |
| IN8bio, Inc. | -30 Million USD | 792.388% |
| Kodiak Sciences Inc. | -260.49 Million USD | 179.759% |
| Annexon, Inc. | -134.23 Million USD | 254.775% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 277.327% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 439.33% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 758.651% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 156.722% |
| Eyenovia, Inc. | -27.26 Million USD | 862.13% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -862.276% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 38934.579% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 371.929% |
| Arcellx, Inc. | -70.69 Million USD | 393.91% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 601.351% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 255.262% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 791.697% |
| Moolec Science SA | -51.78 Million USD | 501.177% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 496.718% |
| Geron Corporation | -184.12 Million USD | 212.838% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 594.985% |
| Royalty Pharma plc | 1.13 Billion USD | 81.692% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 252.818% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 2436.59% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 1078.029% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 221.026% |
| Humacyte, Inc. | -110.77 Million USD | 287.554% |
| Structure Therapeutics Inc. | -89.62 Million USD | 331.829% |
| 89bio, Inc. | -142.18 Million USD | 246.119% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 401.283% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 2102.168% |
| Genelux Corporation | -28.29 Million USD | 834.23% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 814.829% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 217.302% |
| Notable Labs, Ltd. | -11.26 Million USD | 1944.505% |
| Liquidia Corporation | -78.5 Million USD | 364.662% |
| Mustang Bio, Inc. | -51.6 Million USD | 502.63% |
| Immunovant, Inc. | -259.33 Million USD | 180.114% |
| Quantum-Si incorporated | -95.96 Million USD | 316.512% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 385.2% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 1172.004% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 316.444% |
| Acasti Pharma Inc. | -12.85 Million USD | 1716.471% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 1025.133% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1401.65% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 213.911% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 4930.04% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 1766.119% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 804.503% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 632.895% |
| PepGen Inc. | -78.62 Million USD | 364.245% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 797.924% |
| United Therapeutics Corporation | 984.8 Million USD | 78.903% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 1033.356% |
| Solid Biosciences Inc. | -96.01 Million USD | 316.388% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 4436.147% |
| Immuneering Corporation | -53.47 Million USD | 488.552% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 4184.211% |
| Silo Pharma, Inc. | -3.7 Million USD | 5714.234% |
| Belite Bio, Inc | -31.63 Million USD | 756.819% |
| XOMA Corporation | -40.83 Million USD | 608.841% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 482.167% |
| Bionomics Limited | -15.49 Billion USD | 101.341% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 347.383% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 812.573% |
| uniQure N.V. | -308.47 Million USD | 167.352% |
| Cassava Sciences, Inc. | -97.21 Million USD | 313.713% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2941.533% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 268.326% |
| Forte Biosciences, Inc. | -31.47 Million USD | 760.074% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 2633.193% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 814.755% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 38934.579% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 892.029% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 1360.328% |
| Altimmune, Inc. | -88.44 Million USD | 334.903% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 237.063% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 812.573% |
| Compugen Ltd. | -18.75 Million USD | 1207.844% |
| Peak Bio, Inc. | -1259.26 USD | 16499075.589% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 551.182% |
| Benitec Biopharma Inc. | -21.75 Million USD | 1055.197% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 161.326% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 350.458% |
| Zura Bio Limited | -60.36 Million USD | 444.21% |
| PolyPid Ltd. | -23.86 Million USD | 970.585% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 1420.652% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 350.458% |
| Instil Bio, Inc. | -156.08 Million USD | 233.108% |
| argenx SE | -295.05 Million USD | 170.416% |
| Immunome, Inc. | -106.8 Million USD | 294.526% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 588.928% |
| Verona Pharma plc | -54.36 Million USD | 482.139% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 307.938% |
| Shattuck Labs, Inc. | -87.29 Million USD | 337.995% |
| CervoMed Inc. | -2.17 Million USD | 9666.167% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 266.677% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 1660.266% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 577.018% |
| Moolec Science SA | -51.78 Million USD | 501.177% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 1201628.129% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 253.766% |
| AnaptysBio, Inc. | -163.61 Million USD | 226.981% |
| Design Therapeutics, Inc. | -66.86 Million USD | 410.737% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 355.196% |
| NeurAxis, Inc. | -14.62 Million USD | 1520.452% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 648.453% |
| Lumos Pharma, Inc. | -34.03 Million USD | 710.463% |
| Achilles Therapeutics plc | -69.66 Million USD | 398.234% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 307.938% |
| 180 Life Sciences Corp. | -19.93 Million USD | 1142.206% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -6805.268% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 8191983.228% |
| Nutriband Inc. | -5.48 Million USD | 3887.659% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 306.327% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 527.438% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 369.506% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 711.613% |
| MoonLake Immunotherapeutics | -36 Million USD | 677.009% |
| Palisade Bio, Inc. | -12.3 Million USD | 1789.146% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 593.222% |
| Beam Therapeutics Inc. | -132.52 Million USD | 256.772% |
| Neurogene Inc. | -36.31 Million USD | 672.087% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 227.139% |
| AEON Biopharma, Inc. | -52.55 Million USD | 495.321% |
| Sesen Bio, Inc. | -19.88 Million USD | 1144.885% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 390.239% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 1760.274% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 146.79% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 286.226% |
| Athira Pharma, Inc. | -117.67 Million USD | 276.563% |
| Vaccinex, Inc. | -20.25 Million USD | 1125.949% |
| HCW Biologics Inc. | -24.99 Million USD | 931.25% |
| XOMA Corporation | -40.83 Million USD | 608.841% |
| Nektar Therapeutics | -276.05 Million USD | 175.262% |
| Arvinas, Inc. | -367.3 Million USD | 156.565% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 308700.074% |
| Merus N.V. | -154.93 Million USD | 234.095% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 313.25% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 761.988% |
| Rezolute, Inc. | -68.45 Million USD | 403.488% |
| Clene Inc. | -49.5 Million USD | 519.693% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1447.07% |
| BeyondSpring Inc. | -21.02 Million USD | 1088.134% |
| Synlogic, Inc. | -57.28 Million USD | 462.706% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 1845.778% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 2019.13% |
| Peak Bio, Inc. | -1259.26 USD | 16499075.589% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 655.997% |
| Krystal Biotech, Inc. | 10.93 Million USD | -1800.521% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 245.19% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 163.907% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 4598.086% |
| MannKind Corporation | -11.93 Million USD | 1840.367% |
| Ikena Oncology, Inc. | -68.16 Million USD | 404.793% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 1088.651% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 323.564% |
| Gossamer Bio, Inc. | -179.81 Million USD | 215.542% |
| CohBar, Inc. | -11.96 Million USD | 1836.858% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 905.665% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 789.104% |
| Legend Biotech Corporation | -518.25 Million USD | 140.089% |
| Mural Oncology plc | -207.44 Million USD | 200.153% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 267.397% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 1235.966% |
| Disc Medicine, Inc. | -76.42 Million USD | 371.841% |
| Champions Oncology, Inc. | -7.27 Million USD | 2955.484% |
| REGENXBIO Inc. | -263.49 Million USD | 178.85% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 2057.633% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 537.354% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 646.988% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 307.427% |
| Vaxart, Inc. | -82.46 Million USD | 351.943% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -62149.261% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 653.413% |
| Cellectis S.A. | -101.05 Million USD | 305.588% |
| Longeveron Inc. | -21.41 Million USD | 1070.275% |
| Repare Therapeutics Inc. | -93.79 Million USD | 321.507% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 138.764% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 391.932% |
| Revolution Medicines, Inc. | -436.36 Million USD | 147.612% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 3261.848% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 774.036% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 399.662% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 420.962% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 2217.674% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 94.26% |
| Denali Therapeutics Inc. | -145.22 Million USD | 243.065% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 172871.8% |
| Veru Inc. | -93.15 Million USD | 323.037% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 868.674% |
| Cingulate Inc. | -23.53 Million USD | 982.794% |
| Passage Bio, Inc. | -102.06 Million USD | 303.567% |
| Context Therapeutics Inc. | -23.96 Million USD | 966.98% |
| Exicure, Inc. | -16.91 Million USD | 1328.361% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 209.977% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 650.167% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 3292.787% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 212.501% |
| Nuvalent, Inc. | -126.21 Million USD | 264.607% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 2075.768% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 339.143% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 780.215% |
| OmniAb, Inc. | -50.61 Million USD | 510.449% |
| Anew Medical, Inc. | 1.34 Million USD | -15334.302% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 1394.889% |
| Lipocine Inc. | -16.35 Million USD | 1370.572% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 412.927% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 426.29% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 592.407% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 533.142% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 1147.678% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 138.369% |
| Ocugen, Inc. | -63.07 Million USD | 429.378% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 317.028% |
| Q32 Bio Inc. | -112.96 Million USD | 283.926% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 1308.498% |
| Alumis Inc. Common Stock | -154.99 Million USD | 234.048% |
| Equillium, Inc. | -13.33 Million USD | 1658.043% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 444.176% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 2701.017% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 1202.13% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 451.655% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 281.411% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 1230.512% |
| Dominari Holdings Inc. | -22.88 Million USD | 1007.984% |
| Edesa Biotech, Inc. | -8.37 Million USD | 2580.949% |
| vTv Therapeutics Inc. | -20.25 Million USD | 1126.0% |
| Bio-Techne Corporation | 168.1 Million USD | -23.592% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 159.009% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -61.242% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 270.534% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 647.629% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 284.447% |
| Nkarta, Inc. | -117.5 Million USD | 276.82% |
| BioCardia, Inc. | -11.57 Million USD | 1895.567% |
| Iterum Therapeutics plc | -38.37 Million USD | 641.464% |